Analysts Set enGene Holdings Inc. (NASDAQ:ENGN) Target Price at $11.05

Shares of enGene Holdings Inc. (NASDAQ:ENGN) have been given a consensus recommendation of “Hold” by the fourteen research firms that are presently covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation, eight have given a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $11.0455.

ENGN has been the subject of several recent analyst reports. Citizens Jmp reaffirmed a “market perform” rating on shares of enGene in a research note on Wednesday, September 9th. Weiss Ratings reissued a “sell (e+)” rating on shares of enGene in a report on Wednesday, August 12th. Morgan Stanley lowered shares of enGene from an “equal weight” rating to an “underweight” rating and set a $3.00 price target for the company. in a research report on Thursday, June 18th. Wall Street Zen raised shares of enGene from a “strong sell” rating to a “sell” rating in a report on Saturday, August 15th. Finally, HC Wainwright reiterated a “buy” rating and issued a $4.00 price objective on shares of enGene in a research report on Tuesday, September 8th.

enGene Stock Performance

Shares of ENGN opened at $2.00 on Thursday. The stock’s 50-day simple moving average is $1.83 and its 200 day simple moving average is $3.44. The stock has a market capitalization of $134.03 million, a price-to-earnings ratio of -1.77 and a beta of -0.28. The company has a debt-to-equity ratio of 0.11, a quick ratio of 10.21 and a current ratio of 10.21. enGene has a 52-week low of $1.40 and a 52-week high of $12.25.

enGene (NASDAQ:ENGN) last posted its earnings results on Tuesday, September 8th. The company reported ($0.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.04). Research analysts forecast that enGene will post -1.81 EPS for the current fiscal year.

Institutional Trading of enGene

A number of large investors have recently modified their holdings of the business. Perceptive Advisors LLC increased its position in shares of enGene by 179.8% in the fourth quarter. Perceptive Advisors LLC now owns 5,869,076 shares of the company’s stock worth $52,998,000 after purchasing an additional 3,771,840 shares during the last quarter. Cormorant Asset Management LP lifted its position in enGene by 72.1% during the fourth quarter. Cormorant Asset Management LP now owns 4,000,000 shares of the company’s stock valued at $36,120,000 after purchasing an additional 1,676,405 shares during the last quarter. Siren L.L.C. lifted its position in enGene by 57.5% during the first quarter. Siren L.L.C. now owns 5,253,159 shares of the company’s stock valued at $35,774,000 after purchasing an additional 1,916,895 shares during the last quarter. Blue Owl Capital Holdings LP grew its stake in enGene by 2.5% in the 4th quarter. Blue Owl Capital Holdings LP now owns 3,360,937 shares of the company’s stock worth $30,349,000 after buying an additional 82,831 shares in the last quarter. Finally, Eventide Asset Management LLC bought a new position in shares of enGene in the 4th quarter worth $8,578,000. Institutional investors own 64.16% of the company’s stock.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.